Donor-matched Grafts
Donor-matched Grafts - Related Videos
10:29
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
0 Views •
Cited by 4 •
2012
Murine bone marrow transplantation is a widely used technique to study immunological mechanisms governing graft-versus-host disease in humans. The ability to monitor T cell trafficking patterns in vivo allows for detailed analysis of the development and perpetuation of T cell responses during graft-versus-host disease.
02:34
Modeling Preservation Injury in Porcine Donor Kidney: A Procedure to Induce Graft Dysfunction by Subjecting Kidney to Prolonged Cold Ischemia
0 Views •
2025
In this video, we describe a technique to induce preservation injury via the prolonged cold ischemic storage time in porcine donor kidney.
03:35
A Technique for Human Skin Grafting in a Mouse Model
0 Views •
2025
This video demonstrates a method for grafting human skin onto an immunodeficient mouse with a suppressed neutrophil response. The method involves applying human split-thickness skin to the mouse's graft bed, sealing it, and covering it for recovery. Eventually, the human skin adheres to the mouse's skin, establishing vascularization and circulation, resulting in a successful skin xenograft.
07:37
Mouse Models for Graft Arteriosclerosis
0 Views •
Cited by 17 •
2013
We describe protocols for our mouse graft arteriosclerois (GA) models which involve interposition of a mouse vessel segment into a recipient of the same inbred strain. By backcrossing additional genetic changes into the vessel donor, the model can assess the effect of specific genes on GA.
12:13
Ex Situ Normothermic Machine Perfusion of Donor Livers
0 Views •
Cited by 21 •
2015
Here we present a protocol describing oxygenated ex situ machine perfusion of donor liver grafts. This article contains a step by step protocol to procure and prepare the liver graft for machine perfusion, prepare the perfusion fluid, prime the perfusion machine and perform oxygenated normothermic machine perfusion of the liver graft.
FAQs
Blood-group compatibility and HLA matching address different biological features of transplantation. Blood-group matching considers a major compatibility characteristic, whereas HLA matching compares markers that help distinguish the body's own cells from foreign cells. Together, these factors help identify a graft less likely to provoke immune injury, although neither measure guarantees complete acceptance or eliminates the need for follow-up.
Recipient T cells can recognize mismatched donor HLA markers as foreign. This recognition activates an immune response directed against the transplanted cells, tissue, or organ, which can impair graft function and produce rejection. The degree of biological mismatch therefore matters because it influences how readily the recipient's immune system identifies the graft as a target.
Closer matching can improve engraftment and transplant outcomes, but it does not make donor and recipient biologically identical. Residual differences may still be recognized by recipient immune cells, so patients may require immunosuppressive therapy and continued monitoring. This distinction is important when interpreting matching as a way to reduce risk rather than as a guarantee of permanent graft acceptance.
Selection commonly considers the compatibility of the donor and recipient blood groups together with their HLA markers. These data help guide the choice among potential cells, tissues, or organs by identifying pairings that may limit immune recognition. The resulting assessment supports transplantation planning, while later clinical monitoring remains necessary to evaluate graft function and possible rejection.
Donor matching is central to both organ transplantation and hematopoietic stem-cell transplantation. In each setting, compatibility information helps identify a suitable donor-recipient pairing and supports the goal of successful engraftment or graft function. The specific transplanted material differs between these applications, but immune recognition and the possibility of rejection remain important considerations.
Immunosuppressive therapy may be needed even when donor and recipient are closely matched, because matching does not eliminate immune injury. By reducing immune activity, this therapy also raises susceptibility to opportunistic infections. Consequently, transplantation research and care must consider two linked outcomes: protecting the graft from rejection while recognizing the infection risks associated with immunosuppression.